Assess whether a CMO finding is a delay or a refuse-to-file risk (7fc935)

Situation

After a boxed-warning proposal from the review division, CMC comparability package for a site change is what 505(b)(2) development lead can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with A CMO finding is a delay versus A refuse-to-file risk on this Clinical and Evidence Strategy file.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose A CMO finding is a delay / A refuse-to-file risk using CMC comparability package for a site change after a boxed-warning proposal from the review division.

Hypotheses to test

• A boxed-warning proposal from the review division is noise around an already-controlled Clinical and Evidence Strategy process in a mid-size sponsor after a complete response letter, given CMC comparability package for a site change.
• A boxed-warning proposal from the review division is the event in CMC comparability package for a site change that forces A CMO finding is a delay for 505(b)(2) development lead under Pharma & Life Sciences.
• CMC comparability package for a site change shows a one-file miss after a boxed-warning proposal from the review division, not a Clinical and Evidence Strategy program failure.
• CMC comparability package for a site change cannot decide a CMO finding is yet after a boxed-warning proposal from the review division; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether CMC comparability package for a site change supports the labeled claim 505(b)(2) development lead would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a boxed-warning proposal from the review division and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a boxed-warning proposal from the review division). The follow-on Clinical and Evidence Strategy action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.